Biography/Memoir

AMA moves toward psychedelic therapy reimbursement…

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC [partnered with MAPS and Rick Doblin] and [Peter Theil & Christian Angermayer backed] COMPASS Pathways…

On March 3 [2023], the AMA published its Panel Actions summary which included the approval of the new Current Procedural Terminology (CPT) III code… the application, “Continuous In-Person Monitoring and Intervention during Psychedelic Medication Therapy,” was a collaboration between both companies, which are leading research efforts currently in the final stages prior to applying with the FDA… while the approval of psilocybin is expected sometime after 2025, the new code would make the common language available for those providing psychological support within trials… as reimbursement following the new CPT code will not be mandatory… it will largely be a question of the payers’ willingness to look at the published clinical data and trust that it can be replicated in real-world conditions, keeping in mind that it is directed to patients who have not responded to traditional standard of care and therefore have few remaining alternatives.

Original Article (Business Insider):
AMA moves toward psychedelic therapy reimbursement, filing a gap in regulations
Artwork Fair Use: Blaine20

Biography/Memoir

Patented…

Biography/Memoir

…launch of…